Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Ormeci, Aslı; Emrence, Zeliha; Baran, B.; Gokturk, S.; Soyer, O.; Evirgen, S.; Akyuz, Filiz; Karaca, C.; Besisik, Selman; Kaymakoglu, Sabahattin; Ustek, D.; Demir, K.

Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Ormeci A., Emrence Z., Baran B., Gokturk S., Soyer O. M., Evirgen S., ...More

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.20, no.5, pp.879-885, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 20 Issue: 5
Publication Date: 2016
Journal Name: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.879-885
Keywords: Helicobacter pylori, CYP2C19, Polymorphism, Pantoprazole, Rabeprazole, PROTON PUMP INHIBITORS, CYP2C19 POLYMORPHISM, OMEPRAZOLE METABOLISM, GENETIC POLYMORPHISMS, S-MEPHENYTOIN, CLARITHROMYCIN, LANSOPRAZOLE, AMOXICILLIN, RESISTANCE, INFECTION
Istanbul University Affiliated: Yes

Abstract

OBJECTIVE: Cytochrome P450 2C19 (CYP2C19) polymorphisms play an important role in the metabolism of proton pump inhibitors. Rabeprazole is primarily metabolized via non-enzymatic pathways. In this study, we determined whether rabeprazole- and pantoprazole-based eradication treatments were influenced by CYP2C19 polymorphisms.